English
This article is from PLoS Currents , volume 3 . Abstract Women with early stage breast cancer frequently receive adjuvant chemotherapy to prevent recurrence; however, not all patients benefit. Recently, gene expression marker panels, such as Oncotype DX, that may better predict risk of breast cancer recurrence have become commercially available and are being used to guide treatment decisions. Oncotype DX analyzes the expression of 21 genes within a tumor to determine a recurrence score that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis, as well as response to adjuvant treatment. We examined the published literature on the analytic validity, clinical validity, and clinical utility of Oncotype DX in guiding adjuvant treatment decisions in women with lymph node-positive breast cancer.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Use of Oncotype DX in Women with Node-Positive Breast Cancer. · Ishibe, Naoko, Schully, Sheri, Freedman, Andrew, Ramsey, Scott David · Internet Archive